Volume 28, Number 12—December 2022
Research
Observational Cohort Study of Evolving Epidemiologic, Clinical, and Virologic Features of Monkeypox in Southern France
Table 1
Variable | No. patients† |
---|---|
Age, y, median (IQR) |
36 (30–42) |
Sex | |
F | 3 (2.2) |
M |
133 (97.8) |
Sexual orientation | |
Men who have sex with men | 125 (91.9) |
Using PrEP | 30 (24) |
Heterosexual men | 2 (1.5) |
Heterosexual women |
3 (2.2) |
History of smallpox vaccination | |
Childhood vaccine | 7 (5.1) |
Postexposure vaccine | 6 (4.4) |
Preexposure vaccine |
2 (1.5) |
HIV-positive | |
Total | 21 (15.4) |
<500 CD4/mm3 | 5 (23.8) |
<200 CD4/mm3 |
0 |
Possible exposure to monkeypox | |
Sexual partner with monkeypox | 21 (15.4) |
New sexual partners‡ | 115 (84.6) |
Attendance at a Pride event | 7 (5.2) |
Recent travel to an endemic country | 0 |
Recent travel to an epidemic country | 17 (12.5) |
*Values are no. (%) patients except as indicated. PrEP, preexposure prophylaxis; CD4, CD4 T lymphocyte. †Total number of patients in the study was 136. ‡Single or multiple new sexual partners in the previous 21 d.
Page created: October 04, 2022
Page updated: November 21, 2022
Page reviewed: November 21, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.